Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Physical Exercise Modulates miR-21-5p, miR-129-5p, miR-378-5p, and miR-188-5p Expression in Progenitor Cells Promoting Osteogenesis.

Valenti MT, Deiana M, Cheri S, Dotta M, Zamboni F, Gabbiani D, Schena F, Dalle Carbonare L, Mottes M.

Cells. 2019 Jul 19;8(7). pii: E742. doi: 10.3390/cells8070742.

2.

Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate.

Besio R, Garibaldi N, Leoni L, Cipolla L, Sabbioneda S, Biggiogera M, Mottes M, Aglan M, Otaify GA, Temtamy SA, Rossi A, Forlino A.

Dis Model Mech. 2019 Jun 20;12(6). pii: dmm038521. doi: 10.1242/dmm.038521.

3.

Runx2 stimulates neoangiogenesis through the Runt domain in melanoma.

Cecconi D, Brandi J, Manfredi M, Serena M, Carbonare LD, Deiana M, Cheri S, Parolini F, Gandini A, Marchetto G, Innamorati G, Avanzi F, Antoniazzi F, Marengo E, Tiso N, Mottes M, Zipeto D, Valenti MT.

Sci Rep. 2019 May 29;9(1):8052. doi: 10.1038/s41598-019-44552-1.

4.

Relationship Between Vertebral Fractures, Bone Mineral Density, and Osteometabolic Profile in HIV and Hepatitis B and C-Infected Patients Treated With ART.

Dalla Grana E, Rigo F, Lanzafame M, Lattuada E, Suardi S, Mottes M, Valenti MT, Dalle Carbonare L.

Front Endocrinol (Lausanne). 2019 May 14;10:302. doi: 10.3389/fendo.2019.00302. eCollection 2019.

5.

Effects of Oral Anticoagulant Therapy on Gene Expression in Crosstalk between Osteogenic Progenitor Cells and Endothelial Cells.

Dalle Carbonare L, Mottes M, Brunelli A, Deiana M, Cheri S, Suardi S, Valenti MT.

J Clin Med. 2019 Mar 8;8(3). pii: E329. doi: 10.3390/jcm8030329.

6.

New Insights into the Runt Domain of RUNX2 in Melanoma Cell Proliferation and Migration.

Deiana M, Dalle Carbonare L, Serena M, Cheri S, Parolini F, Gandini A, Marchetto G, Innamorati G, Manfredi M, Marengo E, Brandi J, Cecconi D, Mori A, Mina MM, Antoniazzi F, Mottes M, Tiso N, Malerba G, Zipeto D, Valenti MT.

Cells. 2018 Nov 20;7(11). pii: E220. doi: 10.3390/cells7110220.

7.

Ectopic expression of the osteogenic master gene RUNX2 in melanoma.

Valenti MT, Dalle Carbonare L, Mottes M.

World J Stem Cells. 2018 Jul 26;10(7):78-81. doi: 10.4252/wjsc.v10.i7.78.

8.

An integrated approach identifies new oncotargets in melanoma.

Cecconi D, Carbonare LD, Mori A, Cheri S, Deiana M, Brandi J, Degaetano V, Masiero V, Innamorati G, Mottes M, Malerba G, Valenti MT.

Oncotarget. 2017 Dec 15;9(14):11489-11502. doi: 10.18632/oncotarget.23727. eCollection 2018 Feb 20.

9.

Role of microRNAs in progenitor cell commitment and osteogenic differentiation in health and disease (Review).

Valenti MT, Dalle Carbonare L, Mottes M.

Int J Mol Med. 2018 May;41(5):2441-2449. doi: 10.3892/ijmm.2018.3452. Epub 2018 Feb 1. Review.

PMID:
29393379
10.

Runx2 overexpression compromises bone quality in acromegalic patients.

Valenti MT, Mottes M, Cheri S, Deiana M, Micheletti V, Cosaro E, Davì MV, Francia G, Dalle Carbonare L.

Endocr Relat Cancer. 2018 Mar;25(3):269-277. doi: 10.1530/ERC-17-0523. Epub 2018 Jan 2.

PMID:
29295822
11.

Clodronate as a Therapeutic Strategy against Osteoarthritis.

Valenti MT, Mottes M, Biotti A, Perduca M, Pisani A, Bovi M, Deiana M, Cheri S, Dalle Carbonare L.

Int J Mol Sci. 2017 Dec 13;18(12). pii: E2696. doi: 10.3390/ijms18122696.

12.

Bone histomorphometry in acromegaly patients with fragility vertebral fractures.

Dalle Carbonare L, Micheletti V, Cosaro E, Valenti MT, Mottes M, Francia G, Davì MV.

Pituitary. 2018 Feb;21(1):56-64. doi: 10.1007/s11102-017-0847-1.

PMID:
29214508
13.

Can half-marathon affect overall health? The yin-yang of sport.

Dalle Carbonare L, Manfredi M, Caviglia G, Conte E, Robotti E, Marengo E, Cheri S, Zamboni F, Gabbiani D, Deiana M, Cecconi D, Schena F, Mottes M, Valenti MT.

J Proteomics. 2018 Jan 6;170:80-87. doi: 10.1016/j.jprot.2017.09.004. Epub 2017 Sep 6.

PMID:
28887210
14.

Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients.

Dalle Carbonare L, Mottes M, Malerba G, Mori A, Zaninotto M, Plebani M, Dellantonio A, Valenti MT.

Int J Mol Sci. 2017 Jun 13;18(6). pii: E1261. doi: 10.3390/ijms18061261.

15.

Role of autophagy in bone and muscle biology.

Valenti MT, Dalle Carbonare L, Mottes M.

World J Stem Cells. 2016 Dec 26;8(12):396-398. doi: 10.4252/wjsc.v8.i12.396.

16.

Osteogenic Differentiation in Healthy and Pathological Conditions.

Valenti MT, Dalle Carbonare L, Mottes M.

Int J Mol Sci. 2016 Dec 27;18(1). pii: E41. doi: 10.3390/ijms18010041. Review.

17.

The recurrent causal mutation for osteogenesis imperfecta type V occurs at a highly methylated CpG dinucleotide within the IFITM5 gene.

Corradi M, Monti E, Venturi G, Gandini A, Mottes M, Antoniazzi F.

J Pediatr Genet. 2014 Mar;3(1):35-9. doi: 10.3233/PGE-14079.

18.

Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen.

Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M, Vincenzi M, Valenti MT, Valli M, Pelilli E, Boner A, Mottes M, Antoniazzi F.

J Bone Miner Res. 2012 Mar;27(3):723-8. doi: 10.1002/jbmr.1480.

19.

Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix.

Valli M, Barnes AM, Gallanti A, Cabral WA, Viglio S, Weis MA, Makareeva E, Eyre D, Leikin S, Antoniazzi F, Marini JC, Mottes M.

Clin Genet. 2012 Nov;82(5):453-9. doi: 10.1111/j.1399-0004.2011.01794.x. Epub 2011 Oct 19.

20.

Hyperuricemia cosegregating with osteogenesis imperfecta is associated with a mutation in GPATCH8.

Kaneko H, Kitoh H, Matsuura T, Masuda A, Ito M, Mottes M, Rauch F, Ishiguro N, Ohno K.

Hum Genet. 2011 Nov;130(5):671-83. doi: 10.1007/s00439-011-1006-9. Epub 2011 May 19.

PMID:
21594610
21.

Current and emerging treatments for the management of osteogenesis imperfecta.

Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F.

Ther Clin Risk Manag. 2010 Sep 7;6:367-81.

22.

Characterization and functional analysis of cis-acting elements of the human farnesyl diphosphate synthetase (FDPS) gene 5' flanking region.

Romanelli MG, Lorenzi P, Sangalli A, Diani E, Mottes M.

Genomics. 2009 Mar;93(3):227-34. doi: 10.1016/j.ygeno.2008.11.002. Epub 2008 Dec 12.

23.

Wound repair capability in EDS fibroblasts can be retrieved by exogenous type V collagen.

Viglio S, Zoppi N, Sangalli A, Gallanti A, Barlati S, Mottes M, Colombi M, Valli M.

ScientificWorldJournal. 2008 Oct 3;8:956-8. doi: 10.1100/tsw.2008.131.

24.

Genetic testing for adult-type hypolactasia in Italian families.

Mottes M, Belpinati F, Milani M, Saccomandi D, Petrelli E, Calacoci M, Chierici R, Pignatti PF, Borgna-Pignatti C.

Clin Chem Lab Med. 2008;46(7):980-4. doi: 10.1515/CCLM.2008.189.

PMID:
18605960
25.

Rescue of migratory defects of Ehlers-Danlos syndrome fibroblasts in vitro by type V collagen but not insulin-like binding protein-1.

Viglio S, Zoppi N, Sangalli A, Gallanti A, Barlati S, Mottes M, Colombi M, Valli M.

J Invest Dermatol. 2008 Aug;128(8):1915-9. doi: 10.1038/jid.2008.33. Epub 2008 Feb 28.

26.

Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.

Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Körkkö J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH.

Hum Mutat. 2007 Mar;28(3):209-21. Review.

27.

Osteogenesis imperfecta: clinical, biochemical and molecular findings.

Venturi G, Tedeschi E, Mottes M, Valli M, Camilot M, Viglio S, Antoniazzi F, Tatò L.

Clin Genet. 2006 Aug;70(2):131-9. Erratum in: Clin Genet. 2006 Nov;70(5):455.

PMID:
16879195
28.

The genetic background of osteoporosis in cystic fibrosis: association analysis with polymorphic markers in four candidate genes.

Castellani C, Malerba G, Sangalli A, Delmarco A, Petrelli E, Rossini M, Assael BM, Mottes M.

J Cyst Fibros. 2006 Dec;5(4):229-35. Epub 2006 May 18.

29.

Osteoporosis in beta-thalassemia: Clinical and genetic aspects.

Origa R, Fiumana E, Gamberini MR, Armari S, Mottes M, Sangalli A, Paglietti E, Galanello R, Borgna-Pignatti C.

Ann N Y Acad Sci. 2005;1054:451-6.

PMID:
16339696
30.

Linkage analysis for prenatal diagnosis in a familial case of Stickler syndrome.

Lisi V, Guala A, Lopez A, Vitali M, Spadoni E, Olivieri C, Danesino C, Mottes M.

Genet Couns. 2002;13(2):163-70.

PMID:
12150217
31.

Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men.

Braga V, Sangalli A, Malerba G, Mottes M, Mirandola S, Gatti D, Rossini M, Zamboni M, Adami S.

Calcif Tissue Int. 2002 Jun;70(6):457-62. Epub 2002 May 27.

PMID:
12016463
32.
33.

Osteogenesis imperfecta at the beginning of bone and joint decade.

Primorac D, Rowe DW, Mottes M, Barisić I, Anticević D, Mirandola S, Gomez Lira M, Kalajzić I, Kusec V, Glorieux FH.

Croat Med J. 2001 Aug;42(4):393-415. Review.

34.

Stickler syndrome and vitreoretinal degeneration: correlation between locus mutation and vitreous phenotype. Apropos of a case.

Parentin F, Sangalli A, Mottes M, Perissutti P.

Graefes Arch Clin Exp Ophthalmol. 2001 Apr;239(4):316-9.

PMID:
11450497
35.

A novel 4-bp deletion creates a premature stop codon and dramatically decreases HEXB mRNA levels in a severe case of Sandhoff disease.

Gomez-Lira M, Mottes M, Perusi C, Pignatti PF, Rizzuto N, Gatti R, Salviati A.

Mol Cell Probes. 2001 Apr;15(2):75-9.

PMID:
11292324
36.

Autosomal dominant benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24.

Floreani A, Molaro M, Mottes M, Sangalli A, Baragiotta A, Roda A, Naccarato R, Clementi M.

Am J Med Genet. 2000 Dec 18;95(5):450-3.

PMID:
11146465
37.

Association of CTR and COLIA1 alleles with BMD values in peri- and postmenopausal women.

Braga V, Mottes M, Mirandola S, Lisi V, Malerba G, Sartori L, Bianchi G, Gatti D, Rossini M, Bianchini D, Adami S.

Calcif Tissue Int. 2000 Nov;67(5):361-366.

PMID:
11136533
38.

Osteogenesis imperfecta: practical treatment guidelines.

Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tatò L.

Paediatr Drugs. 2000 Nov-Dec;2(6):465-88. Review.

PMID:
11127846
39.
40.

Detection of mutations in the ALD gene (ABCD1) in seven Italian families: description of four novel mutations.

Lira MG, Mottes M, Pignatti PF, Medica I, Uziel G, Cappa M, Bertini E, Rizzuto N, Salviati A.

Hum Mutat. 2000 Sep;16(3):271.

PMID:
10980539
41.

Allelic frequencies of FBN1 gene polymorphisms and genetic analysis of italian families with Marfan syndrome.

Mottes M, Mirandola S, Rigatelli F, Zolezzi F, Lisi V, Gordon D, Pignatti PF.

Hum Hered. 2000 May-Jun;50(3):175-9.

PMID:
10686496
42.

Four new cases of lethal osteogenesis imperfecta due to glycine substitutions in COL1A1 and genes. Mutations in brief no. 152. Online.

Mottes M, Gomez Lira M, Zolezzi F, Valli M, Lisi V, Freising P.

Hum Mutat. 1998;12(1):71-2.

PMID:
10627137
43.

Two novel frameshift mutations in the adrenoleukodystrophy gene in Italian patients.

Gomez-Lira M, Perusi C, Mottes M, Pignatti PF, Uziel G, Rizzuto N, Salviati A.

J Neurol Sci. 1999 May 1;165(1):62-5.

PMID:
10426149
44.
45.

Two novel missense mutations causing adrenoleukodystrophy in Italian patients.

Perusi C, Gomez-Lira M, Mottes M, Pignatti PF, Bertini E, Cappa M, Vigliani MC, Schiffer D, Rizzuto N, Salviati A.

Mol Cell Probes. 1999 Jun;13(3):179-82.

PMID:
10369742
46.

Molecular genetic characterization of two metachromatic leukodystrophy patients who carry the T799G mutation and show different phenotypes; description of a novel null-type mutation.

Gomez-Lira M, Perusi C, Mottes M, Pignatti PF, Manfredi M, Rizzuto N, Salviati A.

Hum Genet. 1998 Apr;102(4):459-63. Erratum in: Hum Genet 1998 May;102(5):602.

PMID:
9600244
47.

A novel mutation which represents the fifth non-pathogenic polymorphism in the coding sequence of the arylsulfatase A gene.

Perusi C, Gomez-Lira M, Mottes M, Pignatti PF, Rizzuto N, Salviati A.

Mol Cell Probes. 1997 Dec;11(6):449-51.

PMID:
9500813
48.

Splicing mutation causes infantile Sandhoff disease.

Gomez-Lira M, Perusi C, Mottes M, Pignatti PF, Rizzuto N, Gatti R, Salviati A.

Am J Med Genet. 1998 Jan 23;75(3):330-3. No abstract available.

PMID:
9475608
49.

Mutation producing alternative splicing of exon 26 in the COL1A2 gene causes type IV osteogenesis imperfecta with intrafamilial clinical variability.

Zolezzi F, Valli M, Clementi M, Mammi I, Cetta G, Pignatti PF, Mottes M.

Am J Med Genet. 1997 Aug 22;71(3):366-70.

PMID:
9268111
50.

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tató L.

J Pediatr. 1996 Sep;129(3):432-9.

PMID:
8804334

Supplemental Content

Loading ...
Support Center